Our latest articles
The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.
Ayvakit hits in its pivotal indolent systemic mastocytosis trial, but a dwindling effect size reignites commercial concerns.
Six months on from axing Epizyme’s PRMT-targeting projects GSK says no to Ideaya’s Mat2A work.
Early data in thyroid eye disease impress, but unanswered questions include the size of the market.
Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.